Thrombolysis with Reteplase in Acute Pulmonary Embolism
ConclusionsDouble bolus reteplase given with heparin is effective in the treatment of high, intermediate risk pulmonary embolism with minimal risk of bleeding.
Publication date: Available online 22 September 2020Source: Academic RadiologyAuthor(s): Waqas T. Qureshi, Rohit Malhotra, Eric J. Schmidlin, Mohamed Ahmed, Amartya Kundu, Abdul Moiz Hafiz, Jennifer Walker, Nikolaos Kakouros
Publication date: Available online 21 September 2020Source: Academic RadiologyAuthor(s): Alireza Zali, Mohammad-Reza Sohrabi, Ali Mahdavi, Nastaran Khalili, Morteza Sanei Taheri, Ali Maher, Mohammadmehdi Sadoughi, Afshin Zarghi, Seyed Ali Ziai, Abbas Arjmand Shabestari, Mehrdad Bakhshayeshkaram, Hamidreza Haghighatkhah, Babak Salevatipour, Alireza Abrishami, Masoomeh Raoufi, Pooneh Dehghan, Arash Khameneh Bagheri, Reza Jalili Khoshnoud, Khatereh Hanani
Publication date: Available online 22 September 2020Source: Social Science &MedicineAuthor(s): Elise Trott Jaramillo, Cathleen E. Willging
AbstractObjectivesThe OVID study will demonstrate whether prophylactic-dose enoxaparin improves survival and reduces hospitalizations in symptomatic ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation.Trial designThe OVID study is conducted as a multicentre open-label superiority randomised controlled trial.ParticipantsInclusion Criteria1. Signed patient informed consent after being fully informed about the study ’s background.2. Patients aged 50 years or older with a positive test for SARS-...
This study utilizes a national electronic health record (EHR) database to understand clinical outcomes with use of second-line treatments including: thrombopoietin receptor agonists (specifically, eltrombopag and romiplostim), rituximab, and splenectomy.METHODS: Utilizing the Optum EHR database, we identified patients who initiated a second-line treatment from Jan. 1, 2009 to Sep. 30, 2016 for primary or unspecified ITP. Additionally, patients included in the analysis had the following characteristics: 18 years or older; previous treatment with corticosteroids or immune globulin products; and active in the database for at ...
ConclusionsOver the last two decades Polish urban stroke units may have achieved a significant reduction of the occurrence of some noninfectious complications (i.e. MI, exacerbated CHF and DVT). However, the list of conditions associated with stroke unit mortality includes not only MI and exacerbated CHF but also PE, gastrointestinal bleeding and recurrent stroke.
Abstract PURPOSE: The findings from the observational studies comparing the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) for atrial fibrillation (AF) and venous thromboembolism (VTE) are inconsistent. We conducted separate meta-analyses examining the efficacy/effectiveness and safety of NOACs versus VKAs by disease (AF vs VTE), study design (randomized controlled trials [RCTs] vs observational studies), and NOAC (dabigatran, rivaroxaban, apixaban, and edoxaban). METHODS: The main data sources included PubMed/MEDLINE, EMBASE, Web of Scienc...
Conclusion This study will provide important information regarding the effectiveness and safety of rivaroxaban treatment in Japanese patients with NVAF among general practitioners.
Conclusion In this small case series, reversal of NOAC with FEIBA was not associated with ICH expansion or any thrombotic or hemorrhagic complications.